Novo Nordisk Instant Savings Card

Details of Offer Including Restrictions on Eligibility and Other Limitations

Restrictions & Limitations: You are not eligible if prescriptions are paid by any state or other federally funded programs, including, but not limited to Medicare, Medicaid, Medigap, VA, DOD, or TRICARE, or where prohibited by law. Offer not valid for Levemir® FlexPen®, NovoLog® Mix 70/30 FlexPen, or NovoLog® reimbursed in full by any third party payor. Offer limited to 1 card per patient. Offer void where taxed, restricted, or prohibited. Offer only good in the U.S.A. Eligibility is restricted to individuals; no clubs, groups, or organizations. This savings card is not transferable. When you use the Novo Nordisk Instant Savings Card, you are certifying that you understand the program rules, terms and conditions and that you will comply with them.

Offer Details: Pay no more than $25 (up to $100 discount) when you start on a Novo Nordisk product and for each refill for up to 2 years, and no more than $20 (up to $100 discount) for the next prescribed product and each refill for up to 2 years. Offer available for a 30-day supply of Levemir® FlexPen®(insulin detemir [rDNA origin] injection), NovoLog® Mix 70/30 FlexPen® (70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]), and NovoLog® (insulin aspart [rDNA origin] injection). Offer valid for a maximum of $100 off your co-pay for each 30-day supply for a maximum of 24 refills per product over 2 years. Novo Nordisk reserves the right to modify or cancel this program at any time.

Needle Offer: Get 1 free box of Novo Nordisk needles when you activate your Instant Savings Card and enroll in the program. Limit 1 box of needles per person. Needles are sold separately and may require a prescription in some states. Needles and FlexPen® must not be shared. Novo Nordisk reserves the right to modify or cancel this program at any time.

How to use the Novo Nordisk Instant Savings Card: You must present the card to the pharmacist along with your prescription to participate in this program. You are not eligible for these savings offers if prescriptions are paid by any state or federally funded programs, including but not limited to Medicare, Medicaid, Medigap, VA, DOD or TriCare, or where prohibited by law. Each time you use this card, you are certifying that you understand the program rules, terms and conditions and that you will comply with them. Please deduct the amount of the discount from any claim for reimbursement submitted to your insurance company or plan. If you have any questions regarding your eligibility or benefits, or if you wish to discontinue your participation, call the Novo Nordisk Instant Savings Card Program at 1-855-292-5966 (8:00 AM-8:00 PM EST, Monday-Friday).

Selected Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
  • Administration: NovoLog® should generally be given immediately (within 5-10 minutes) prior to the start of a meal. Any change of insulin dose should be made cautiously and only under medical supervision. Changing from one insulin product to another or changing the insulin strength may result in the need for a change in dosage. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity. NovoLog® should be used with a longer-acting insulin.

NovoLog® (insulin aspart [rDNA origin] injection) Indications and Usage

  • NovoLog® (insulin aspart [rDNA origin] injection) is an insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus.

Important Safety Information

Contraindications

  • NovoLog® is contraindicated during episodes of hypoglycemia and in patients hypersensitive to NovoLog® or one of its excipients.

Warnings and Precautions

  • Never Share a NovoLog® FlexPen, NovoLog® FlexTouch®, PenFill® Cartridge, or PenFill® Cartridge Device Between Patients, even if the needle is changed. Sharing poses a risk for transmission of blood-borne pathogens.
  • Administration: NovoLog® should generally be given immediately (within 5-10 minutes) prior to the start of a meal. Any change of insulin dose should be made cautiously and only under medical supervision. Changing from one insulin product to another or changing the insulin strength may result in the need for a change in dosage. As with all insulin preparations, the time course of action of NovoLog® may vary in different individuals or at different times in the same individual and is dependent on many conditions, including injection site, local blood supply, temperature, and level of physical activity. NovoLog® should be used with a longer-acting insulin.
  • Hypoglycemia: Hypoglycemia is the most common adverse effect of insulin therapy. The timing of hypoglycemia may reflect the time-action profile of the insulin formulation. Glucose monitoring is recommended for all patients with diabetes and is particularly important for patients using external pump infusion therapy. Any change of insulin dose should be made cautiously and only under medical supervision.
  • Hypokalemia: Insulin, particularly when given intravenously or in settings of poor glycemic control, can cause hypokalemia. Use caution in patients predisposed to hypokalemia.
  • Renal and Hepatic Impairment: Like all insulins, NovoLog® requirements may be reduced in patients with renal impairment or hepatic impairment.
  • Hypersensitivity and Allergic Reactions: Severe, life-threatening, generalized allergy, including anaphylaxis, may occur with insulin products, including NovoLog®
  • Continuous Subcutaneous Insulin Infusion by External Pump: When used in an external subcutaneous insulin infusion pump, NovoLog® should not be mixed with any other insulin or diluent.
  • Fluid retention and heart failure with concomitant use of PPAR-gamma agonists: Fluid retention and heart failure can occur with concomitant use of thiazolidinediones (TZDs), which are PPAR-gamma agonists, and insulin, including NovoLog®. Patients should be observed for signs and symptoms of heart failure. If heart failure occurs, dosage reduction or discontinuation of the TZD must be considered.

Adverse Reactions

  • Adverse reactions observed with NovoLog® include hypoglycemia, allergic reactions, local injection site reactions, lipodystrophy, rash, and pruritus.

Use in Specific Populations

  • NovoLog® has not been studied in children with type 2 diabetes or in children with type 1 diabetes who are younger than 2 years of age.
  • The background risk of birth defects, pregnancy loss, or other adverse events that exists for all pregnancies is increased in pregnancies complicated by hyperglycemia.

Please click here for Prescribing Information.